Weiping Liu

5.3k total citations · 1 hit paper
182 papers, 2.9k citations indexed

About

Weiping Liu is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Weiping Liu has authored 182 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Pathology and Forensic Medicine, 92 papers in Oncology and 34 papers in Immunology. Recurrent topics in Weiping Liu's work include Lymphoma Diagnosis and Treatment (117 papers), Viral-associated cancers and disorders (60 papers) and Immune Cell Function and Interaction (22 papers). Weiping Liu is often cited by papers focused on Lymphoma Diagnosis and Treatment (117 papers), Viral-associated cancers and disorders (60 papers) and Immune Cell Function and Interaction (22 papers). Weiping Liu collaborates with scholars based in China, Ethiopia and United States. Weiping Liu's co-authors include Jun Zhu, Sha Zhao, Wenyan Zhang, Yuqin Song, Qun‐pei Yang, Xiaopei Wang, Yan Xie, Lingyan Ping, Wen Zheng and Zhitao Ying and has published in prestigious journals such as Nature Medicine, Blood and Cancer.

In The Last Decade

Weiping Liu

168 papers receiving 2.9k citations

Hit Papers

First Human Imaging Studies with the EXPLORER Total-Body ... 2019 2026 2021 2023 2019 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Weiping Liu China 26 1.4k 1.4k 563 434 416 182 2.9k
Samuel A. Jacobs United States 25 1.4k 1.0× 753 0.5× 273 0.5× 434 1.0× 620 1.5× 143 2.9k
Antonio Gutiérrez Spain 28 1.0k 0.7× 978 0.7× 611 1.1× 97 0.2× 290 0.7× 154 3.1k
Gary N. Schwartz United States 29 1.3k 0.9× 470 0.3× 342 0.6× 283 0.7× 944 2.3× 89 3.7k
Flora Zagouri Greece 33 1.7k 1.2× 508 0.4× 285 0.5× 241 0.6× 1.2k 2.8× 301 4.0k
Megan L. Troxell United States 36 1.5k 1.0× 674 0.5× 306 0.5× 556 1.3× 1.3k 3.1× 141 4.3k
David T. Yang United States 33 768 0.5× 653 0.5× 348 0.6× 103 0.2× 1.0k 2.5× 91 2.7k
Audrey Mauguen United States 27 785 0.5× 394 0.3× 131 0.2× 290 0.7× 406 1.0× 111 2.1k
Ellen G. Feigal United States 21 1.5k 1.1× 478 0.3× 228 0.4× 140 0.3× 735 1.8× 43 2.8k
Malin Sund Sweden 31 1.3k 0.9× 332 0.2× 667 1.2× 348 0.8× 1.3k 3.1× 132 4.0k
Jin Ho Paik South Korea 25 948 0.7× 707 0.5× 412 0.7× 76 0.2× 633 1.5× 90 2.3k

Countries citing papers authored by Weiping Liu

Since Specialization
Citations

This map shows the geographic impact of Weiping Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiping Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiping Liu more than expected).

Fields of papers citing papers by Weiping Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiping Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiping Liu. The network helps show where Weiping Liu may publish in the future.

Co-authorship network of co-authors of Weiping Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Weiping Liu. A scholar is included among the top collaborators of Weiping Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weiping Liu. Weiping Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Hui, Weiping Liu, Lan Mi, et al.. (2024). CD93+ Myeloid Cells Suppress T-Cell-Mediated Anti-Tumor Immunity. Blood. 144(Supplement 1). 960–960.
2.
Liu, Yanfei, Lingyan Ping, Yuqin Song, et al.. (2024). Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial. BMC Medicine. 22(1). 107–107. 2 indexed citations
3.
Liu, Yiqi, Chi Zhang, Na Huo, et al.. (2023). Steady Decline of HBV DNA Load under NAs in Lymphoma Patients and a Higher Level of qAnti-HBc Predict HBV Reactivation. Journal of Clinical Medicine. 13(1). 23–23. 4 indexed citations
4.
Yang, Yiming, Xueqin Deng, Ningning Chao, et al.. (2023). High CD8+tumor-infiltrating lymphocytes indicate severe exhaustion and poor prognosis in angioimmunoblastic T-cell lymphoma. Frontiers in Immunology. 14. 1228004–1228004. 9 indexed citations
6.
Shi, Yunfei, Haojie Wang, Mengping Long, et al.. (2023). Genetic abnormalities assist in pathological diagnosis and EBV-positive cell density impact survival in Chinese angioimmunoblastic T-cell lymphoma patients. Chinese Journal of Cancer Research. 35(5). 536–549. 4 indexed citations
7.
Wang, Lisheng, Deyu Meng, Hao Liu, et al.. (2022). Individualized Statistical Modeling of Lesions in Fundus Images for Anomaly Detection. IEEE Transactions on Medical Imaging. 42(4). 1185–1196. 2 indexed citations
8.
Ping, Lingyan, Weiping Liu, Yan Xie, et al.. (2019). Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: a retrospective study. Hematology. 24(1). 413–419. 8 indexed citations
9.
Guan, Pujun, Zihang Chen, Zhen Li, et al.. (2019). Extranodal NK/T-cell lymphoma in adolescents: imaging findings of a consecutive 7-year case series. Journal of International Medical Research. 47(3). 1210–1220. 4 indexed citations
10.
Liu, Weiping, et al.. (2015). [Survey of hospital infection management staff in the Inner Mongolia Autonomous Region].. PubMed. 95(40). 3302–4. 2 indexed citations
11.
Liu, Weiping. (2014). Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin’s lymphoma. World Journal of Gastroenterology. 20(17). 5165–5165. 7 indexed citations
12.
Bi, Chengfeng, et al.. (2013). [Diffuse large B-cell lymphoma of testis: a clinicopathologic and immunophenotypic study of 58 cases].. PubMed. 42(9). 589–92. 1 indexed citations
13.
Min, Min, Li Lin, Chengfeng Bi, et al.. (2012). [Analysis of the immunohistochemical subtypes and prognosis of primary diffuse large B cell lymphoma of the central nervous system].. PubMed. 34(2). 110–6. 3 indexed citations
14.
Shao, Yong, Wei Zhang, Weiping Liu, et al.. (2010). Keratinocytes play a role in the immunity to Herpes simplex virus type 2 infection. Acta Virologica. 54(4). 261–267. 7 indexed citations
15.
Wang, Xiaoqing, Chengfeng Bi, Tianyou Luo, et al.. (2010). [Primary lymphoma of breast: a clinicopathologic, immunophenotypic and prognostic study of 21 cases].. PubMed. 39(5). 302–7. 2 indexed citations
16.
Liu, Weiping. (2007). SHORT-TERM FOREIGN FUNDS, A COMPARATIVE STUDY BETWEEN CHINA AND VICTIM COUNTRIES OF 1997 ASIAN FINANCIAL CRISIS. SSRN Electronic Journal.
17.
Bi, Chengfeng, Lili Jiang, Zheng Li, & Weiping Liu. (2007). [Littoral cell angioma of spleen: a clinicopathologic study of 17 cases].. PubMed. 36(4). 239–43. 9 indexed citations
18.
Liu, Weiping. (2007). AN EMPIRICAL STUDY OF FINANCIAL CRISES AMONG MIDDLE-INCOME COUNTRIES BETWEEN 1993-2003. SSRN Electronic Journal. 1 indexed citations
19.
Liu, Weiping, et al.. (2006). [Clinicopathologic and immunophenotypic analysis of myeloid sarcoma].. PubMed. 35(10). 606–11. 7 indexed citations
20.
Liu, Weiping. (2001). Effects on Debt Service Capacity Indicators' Volatitlity on Sovereigns' Debt Service Capacity. Multinational Business Review. 9(2). 33. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026